GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (HKSE:09688) » Definitions » EV-to-FCF

Zai Lab (HKSE:09688) EV-to-FCF : -9.34 (As of Apr. 20, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Zai Lab EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Zai Lab's Enterprise Value is HK$20,139 Mil. Zai Lab's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-2,156 Mil. Therefore, Zai Lab's EV-to-FCF for today is -9.34.

The historical rank and industry rank for Zai Lab's EV-to-FCF or its related term are showing as below:

HKSE:09688' s EV-to-FCF Range Over the Past 10 Years
Min: -144.51   Med: -7.26   Max: -2.53
Current: -9.39

During the past 10 years, the highest EV-to-FCF of Zai Lab was -2.53. The lowest was -144.51. And the median was -7.26.

HKSE:09688's EV-to-FCF is ranked worse than
100% of 450 companies
in the Biotechnology industry
Industry Median: 2.095 vs HKSE:09688: -9.39

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-20), Zai Lab's stock price is HK$22.80. Zai Lab's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-1.950. Therefore, Zai Lab's PE Ratio (TTM) for today is At Loss.


Zai Lab EV-to-FCF Historical Data

The historical data trend for Zai Lab's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab EV-to-FCF Chart

Zai Lab Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -47.27 -8.11 -4.99 -9.03 -7.95

Zai Lab Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.03 -4.10 -5.27 -8.63 -7.95

Competitive Comparison of Zai Lab's EV-to-FCF

For the Biotechnology subindustry, Zai Lab's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zai Lab's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zai Lab's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Zai Lab's EV-to-FCF falls into.


;
;

Zai Lab EV-to-FCF Calculation

Zai Lab's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=20139.286/-2156.186
=-9.34

Zai Lab's current Enterprise Value is HK$20,139 Mil.
Zai Lab's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-2,156 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zai Lab  (HKSE:09688) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Zai Lab's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=22.80/-1.950
=At Loss

Zai Lab's share price for today is HK$22.80.
Zai Lab's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-1.950.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Zai Lab EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Zai Lab's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Zai Lab Business Description

Traded in Other Exchanges
Address
4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
Executives
Du Ying 2101 Beneficial owner
Fmr Llc 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Wellington Management Group Llp 2102 Investment manager
Janus Henderson Group Plc 2102 Investment manager
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Ubs Group Ag 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd.
Qiming Gp Iv, L.p.
Qiming Venture Partners Iv, L.p.
Qm11 Limited
Invesco Advisers, Inc. 2102 Investment manager
Invesco Developing Markets Fund 2106 Person having a security interest in shares
Baillie Gifford & Co 2102 Investment manager
Citigroup Inc. 2502 Approved lending agent

Zai Lab Headlines

No Headlines